HDAC2 and chronic myelogenous leukemia, BCR-ABL1 positive: According to prior research, the PI3K/Akt signal pathway is dysregulated in response to the activation of BCR–ABL, which is also modulated in response to IM treatment.38 Additionally, the inhibition of PI3K/Akt sensitizes the CML leukemic stem cells to TKIs.39 Liu et al. suggested that PI3K/Akt blocking within the bone marrow stromal cells dramatically reduced the IM resistance induced by HO-1.40 As shown in our study, the Akt signaling pathway had a negative effect on regulating apoptosis, so the HDAC2 effect on Akt activity in CML cells resistant to IM was also investigated.